From a pediatric alopecia areata approval to head-to-head TYK2 data at EADV, here are 7 dermatology stories from September 2026.
Opinion|Podcasts|June 26, 2024
Beyond the Surface: Monitoring your Patients with Moderate to Severe Plaque Psoriasis
Listen
0:00 / 0:00
A panel of dermatologists have a comprehensive discussion on exciting developments in the treatment of plaque psoriasis, focusing on treatment approaches, patient monitoring strategies, and recent clinical trial data.
Advertisement
1:09 Comorbidities in Plaque Psoriasis
5:11 Classifying the Severity of Plaque Psoriasis
8:30 Laboratory Tests for Systemic Therapy
13:22 Monitoring Systemic Therapy in Plaque Psoriasis
16:50 New Oral Systemic Therapies for Plaque Psoriasis
23:23 Efficacy Data on Deucravacitinib
28:03 Long-term Safety Data of Deucravacitinib
34:52 Selecting the Right Treatment for the Right Patient
Advertisement
Related to this article
Oral icotrokinra sustained clearance at scalp, genital, hand/foot, and nail sites through Week 112 in ICONIC-TOTAL, with no rise in adverse event rates.
Zasocitinib achieved PASI 100 in 36.5% of patients vs 13.9% with deucravacitinib at week 16 in the phase 3 LATITUDE Atlas psoriasis trial.
Advertisement
Advertisement
Trending on HCPLive
1
8 Endocrinology Headlines You Missed in Q3 2026
2
Upadacitinib Tops Nemolizumab on Skin, Itch Targets in Indirect Analysis
3
From Injectable to Oral: Optimal Durable Clearance Across the IL-23 Class
4
EADV Congress 2026: Day 3 Recap—5 Headlines to Know
5